Duchenne Muscular Dystrophy is a significant neurodegenerative disorder affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.
Overview
Duchenne Muscular Dystrophy (DMD) is the most common and severe form of childhood muscular dystrophy, affecting approximately 1 in 3,500-5,000 live male births [1]. It is an X-linked recessive disorder caused by mutations in the DMD gene that result in the absence or severe reduction of functional dystrophin protein, leading to progressive muscle degeneration, loss of ambulation, and premature death [2]. [@machine]
Genetics and Molecular Biology
DMD Gene
The DMD gene is one of the largest known human genes, spanning over 2.2 megabases on chromosome Xp21.1. It encodes dystrophin, a critical cytoskeletal protein that provides structural stability to muscle cell membranes [3]. [@effects]
Types of Mutations
Frameshift/nonsense mutations: ~60-70% of cases, cause premature stop codons
Large deletions: ~60-70% of cases, typically involve one or more exons
Duplications: ~10-15% of cases
Small mutations: ~20-25% of cases (missense, splice site, small deletions)
Dystrophin Protein
...
Duchenne Muscular Dystrophy
Introduction
Duchenne Muscular Dystrophy is a significant neurodegenerative disorder affecting millions worldwide. This page provides comprehensive information about the disease, including its mechanisms, symptoms, diagnosis, and treatment approaches.
Overview
Duchenne Muscular Dystrophy (DMD) is the most common and severe form of childhood muscular dystrophy, affecting approximately 1 in 3,500-5,000 live male births [1]. It is an X-linked recessive disorder caused by mutations in the DMD gene that result in the absence or severe reduction of functional dystrophin protein, leading to progressive muscle degeneration, loss of ambulation, and premature death [2]. [@machine]
Genetics and Molecular Biology
DMD Gene
The DMD gene is one of the largest known human genes, spanning over 2.2 megabases on chromosome Xp21.1. It encodes dystrophin, a critical cytoskeletal protein that provides structural stability to muscle cell membranes [3]. [@effects]
Types of Mutations
Frameshift/nonsense mutations: ~60-70% of cases, cause premature stop codons
Large deletions: ~60-70% of cases, typically involve one or more exons
Duplications: ~10-15% of cases
Small mutations: ~20-25% of cases (missense, splice site, small deletions)
Dystrophin Protein
Dystrophin (427 kDa) is a rod-shaped cytoplasmic protein that: [@screening]
Connects the actin cytoskeleton to the dystrophin-associated glycoprotein complex (DGC)
Stabilizes muscle cell membranes during contraction
Prevents membrane damage from mechanical stress
Has multiple neuronal isoforms (Dp140, Dp71) important for cognitive function
Disease Mechanism Flowchart
Mermaid diagram (expand to render)
Pathophysiology
Primary Mechanism
The absence of functional dystrophin leads to: [@twoyear]
Stem cell therapy: Various approaches in development
CRISPR-based gene editing: Preclinical and early clinical stages
Prognosis
Mean life expectancy: Early 30s (historically late teens)
Current improvements: Many patients now living into 40s-50s with modern care
Leading causes of death: Respiratory failure, cardiomyopathy
Quality of life: Significantly improved with multidisciplinary care
Background
The study of Duchenne Muscular Dystrophy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
[Cardiac and skeletal muscle delivery of biotherapeutics with a blood vessel epicardial substance-targeting peptide.](https://pubmed.ncbi.nlm.nih.gov/41506143/) (2026 Jun) - Biomaterials
[Machine learning for site risk prediction in clinical trials: development, external validation, and operational application in site qualification.](https://pubmed.ncbi.nlm.nih.gov/41741318/) (2026 May) - International journal of medical informatics
[Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study.](https://pubmed.ncbi.nlm.nih.gov/41749413/) (2026 Apr) - Journal of cachexia, sarcopenia and muscle
[Screening for brain-related comorbidities in Duchenne muscular dystrophy: Construction, reliability, and validity of the BIND screener.](https://pubmed.ncbi.nlm.nih.gov/41645051/) (2026 Apr) - Developmental medicine and child neurology
[Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial.](https://pubmed.ncbi.nlm.nih.gov/41518520/) (2026 Apr) - Neurology and therapy